<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of hyperthyroidism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of hyperthyroidism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of hyperthyroidism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The diagnosis of hyperthyroidism is usually evident in patients with unequivocal clinical and biochemical manifestations of the disease. Other patients have fewer and less obvious clinical signs but definite biochemical hyperthyroidism. Still others have little or no clinical hyperthyroidism, and their only biochemical abnormality is a low serum thyroid-stimulating hormone (TSH) concentration, a disorder called subclinical hyperthyroidism.</p><p>Following a brief discussion of the clinical manifestations of hyperthyroidism, the diagnosis and evaluation of patients with hyperthyroidism will be presented here. An overview of the clinical manifestations of hyperthyroidism, disorders that cause hyperthyroidism, the diagnosis of hyperthyroidism during pregnancy, and subclinical hyperthyroidism are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults"</a>.)</p><p></p><p class="headingAnchor" id="H25975024"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Hyperthyroid symptoms are nonspecific and may be present in patients with subclinical disease and absent in those with overt disease, especially older adults.</p><p class="headingAnchor" id="H3"><span class="h3">Overt hyperthyroidism</span><span class="headingEndMark"> — </span>Most patients with overt hyperthyroidism have a dramatic constellation of symptoms. These symptoms characteristically include anxiety, emotional lability, weakness, tremor, palpitations, heat intolerance, increased perspiration, and weight loss despite a normal or increased appetite [<a href="#rid1">1,2</a>].</p><p>While the combination of weight loss and increased appetite is a characteristic finding, some patients gain weight, in particular younger patients, due to excessive appetite stimulation [<a href="#rid1">1</a>]. Other symptoms that may be present include hyperdefecation (not diarrhea), urinary frequency, oligomenorrhea or amenorrhea in women, and gynecomastia and erectile dysfunction in men [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p class="headingAnchor" id="H4"><span class="h3">Milder symptoms</span><span class="headingEndMark"> — </span>Patients with mild hyperthyroidism and older patients often have symptoms that are referable to one or only a few organ systems [<a href="#rid5">5</a>]. Isolated symptoms and signs that should lead to evaluation for hyperthyroidism in patients of any age include unexplained weight loss, new onset atrial fibrillation, myopathy, menstrual disorders, and gynecomastia.</p><p>Other conditions that should suggest the possibility of hyperthyroidism include osteoporosis, hypercalcemia, heart failure, premature atrial contractions, shortness of breath, and a deterioration in glycemia in patients with previously diagnosed diabetes. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Older patients</span><span class="headingEndMark"> — </span>In older patients, cardiopulmonary symptoms such as tachycardia (or atrial fibrillation), dyspnea on exertion, and edema may predominate [<a href="#rid1">1,6-8</a>]. They also tend to have more weight loss and less of an increase in appetite [<a href="#rid1">1</a>]. The most dramatic example of this phenomenon is "apathetic thyrotoxicosis," in which older patients have no symptoms except for weakness and asthenia. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Geriatric hyperthyroidism'</a>.)</p><p>Subclinical hyperthyroidism, defined as normal serum levels of free thyroxine (T4) and triiodothyronine (T3) with a suppressed TSH level, is associated with a threefold increase in the risk of atrial fibrillation in older persons  (<a class="graphic graphic_figure graphicRef55024" href="/d/graphic/55024.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/1004.html" rel="external">"Epidemiology, risk factors, and prevention of atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults", section on 'Atrial fibrillation'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination in patients with overt hyperthyroidism may be notable for hyperactivity and rapid speech. Many patients have stare (lid retraction) and lid lag, representing sympathetic hyperactivity. The skin is typically warm and moist, and the hair may be thin and fine. Tachycardia is common, the pulse is irregularly irregular in patients with atrial fibrillation, systolic hypertension may be present, and the precordium is often hyperdynamic [<a href="#rid6">6</a>]. Tremor, proximal muscle weakness, and hyperreflexia are other frequent findings. Exophthalmos, periorbital and conjunctival edema, limitation of eye movement, and infiltrative dermopathy (pretibial myxedema) occur only in patients with Graves' disease. (See  <a class="medical medical_review" href="/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease"</a> and  <a class="medical medical_review" href="/d/html/7826.html" rel="external">"Pretibial myxedema (thyroid dermopathy) in autoimmune thyroid disease"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Thyroid size</span><span class="headingEndMark"> — </span>The presence and size of a goiter depends upon the cause of the hyperthyroidism. (See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid enlargement ranges from minimal to massive in patients with Graves' disease or toxic multinodular goiter. A nonpalpable thyroid occurs commonly in older patients with Graves' disease. (See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism", section on 'Toxic adenoma and toxic multinodular goiter'</a> and  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Geriatric hyperthyroidism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with painless (silent or lymphocytic) thyroiditis may have no, minimal, or modest thyroid enlargement. The absence of any thyroid enlargement should also suggest exogenous hyperthyroidism or struma ovarii. (See  <a class="medical medical_review" href="/d/html/7840.html" rel="external">"Exogenous hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/7829.html" rel="external">"Struma ovarii"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single, palpable nodule raises the possibility of an autonomously functioning thyroid adenoma. (See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism", section on 'Toxic adenoma and toxic multinodular goiter'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The thyroid is painful and tender in subacute (granulomatous) thyroiditis. (See  <a class="medical medical_review" href="/d/html/7832.html" rel="external">"Subacute thyroiditis"</a>.)</p><p></p><p class="headingAnchor" id="H16194856"><span class="h2">Laboratory tests</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid function tests</strong> – All patients with primary hyperthyroidism have a low TSH. The serum TSH concentration alone cannot determine the degree of biochemical hyperthyroidism; serum free T4 and T3 are required to provide this information. However, in laboratories utilizing serum TSH assays with detection limits of 0.01 mU/L (third generation), most patients with overt hyperthyroidism have values &lt;0.05 mU/L. (See  <a class="medical medical_review" href="/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function"</a>.)</p><p></p><p class="bulletIndent1">Most patients with overt hyperthyroidism have high free T4 <strong>and</strong> T3 concentrations. In one study, free T4 and free T3 levels were higher in males aged 20 to 39 years than similarly aged females [<a href="#rid9">9</a>]. In some patients, however, only the serum T3 or serum T4 is elevated  (<a class="graphic graphic_table graphicRef142425" href="/d/graphic/142425.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">In patients with subclinical hyperthyroidism, TSH is below normal (but more frequently &gt;0.05 mU/L) and serum free T4, T3, and free T3 are normal. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong>– Patients with hyperthyroidism may have other nonspecific laboratory findings. As an example, patients with hyperthyroidism tend to have low serum total, low-density (LDL), and high-density lipoprotein (HDL) cholesterol concentrations, which increase after treatment. In addition, the red blood cell mass may be increased in hyperthyroidism, but the plasma volume is increased more, resulting in a normochromic, normocytic anemia. Serum alkaline phosphatase and osteocalcin concentrations may be high, indicative of increased bone turnover. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Metabolic/Endocrine'</a> and  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Hematologic'</a> and  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Bone'</a>.)</p><p></p><p class="headingAnchor" id="H1510489691"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of hyperthyroidism is based upon thyroid function tests  (<a class="graphic graphic_table graphicRef142425" data-inline-graphics="142425" href="/d/graphic/142425.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H210313925"><span class="h2">Thyroid function tests</span><span class="headingEndMark"> — </span>In patients in whom there is a clinical suspicion of hyperthyroidism, the best initial test is serum TSH. If the value is normal, the patient is very unlikely to have primary hyperthyroidism. Many laboratories have instituted algorithms in which serum free T4 and T3 are automatically measured if a low serum TSH value is obtained [<a href="#rid10">10</a>]. If a laboratory is unable to add these determinations to a low TSH value and it will be inconvenient for the patient to return for follow-up testing, it is reasonable to order serum TSH, free T4, and T3 as initial tests in patients in whom the clinical suspicion of hyperthyroidism is high. In addition, if hyperthyroidism is strongly suspected despite a normal or elevated serum TSH value, serum free T4 and T3 should be measured. (See  <a class="medical medical_review" href="/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function"</a>.)</p><p class="headingAnchor" id="H16195383"><span class="h2">Overt hyperthyroidism</span><span class="headingEndMark"> — </span>The diagnosis of overt hyperthyroidism is usually straightforward. Except for laboratory error or assay interference due to <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> ingestion, all patients with low serum TSH and high free T4 and/or T3 concentrations have primary hyperthyroidism. (See <a class="local">'Assay interference with biotin ingestion'</a> below.)</p><p>Most patients with overt hyperthyroidism caused by Graves' disease or nodular goiter have greater increases in serum T3 than in serum T4, due both to a disproportionate increase in thyroidal T3 secretion and increased extrathyroidal conversion of T4 to T3 [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H16194933"><span class="h3">T3-toxicosis</span><span class="headingEndMark"> — </span>Patients with T3-toxicosis by definition have symptoms and signs of hyperthyroidism but only high serum T3 (and low TSH) concentrations. An occasional patient will have normal serum T3 and free T4 levels but will have an elevated serum free T3 [<a href="#rid12">12</a>]. This pattern of test results tends to occur early in the course of hyperthyroidism, a time at which most patients have relatively few symptoms.</p><p class="headingAnchor" id="H16194990"><span class="h3">T4-toxicosis</span><span class="headingEndMark"> — </span>The pattern of low TSH, high serum free T4, and normal T3 concentrations is called T4-toxicosis. It may be found in patients with hyperthyroidism who have a concurrent nonthyroidal illness that decreases extrathyroidal conversion of T4 to T3 [<a href="#rid13">13</a>]. Despite the nonthyroidal illness, these patients remain hyperthyroid and their serum TSH concentrations are low; with recovery from the nonthyroidal illness, serum T3 concentrations rise unless the hyperthyroidism is recognized and treated. (See  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>.)</p><p><a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> inhibits extrathyroidal conversion of T4 to T3 in all patients. Thus, patients with amiodarone-induced hyperthyroidism may also have T4-hyperthyroidism (or at least have serum T3 concentrations that are not as elevated as in patients with Graves' hyperthyroidism). This pattern is present whether the hyperthyroidism is caused by amiodarone-induced thyroiditis or iodide excess [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a>.)</p><p class="headingAnchor" id="H16195081"><span class="h2">Subclinical hyperthyroidism</span><span class="headingEndMark"> — </span>The availability of sensitive assays for TSH resulted in the identification of patients who have low serum TSH concentrations (&lt;0.4 mU/L) but normal serum free T4, T3, and free T3 concentrations, a constellation of biochemical findings defined as subclinical hyperthyroidism. Most of these patients have no clinical manifestations of hyperthyroidism, and those symptoms that are present are mild and nonspecific. Many patients have a multinodular goiter with autonomy (toxic nodular goiter) or mild Graves' disease. Most patients are detected through routine screening of thyroid function. (See  <a class="medical medical_review" href="/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults"</a>.)</p><p class="headingAnchor" id="H16195327"><span class="h2">TSH-induced hyperthyroidism</span><span class="headingEndMark"> — </span>TSH-induced hyperthyroidism is a very rare cause of overt hyperthyroidism, due to either a TSH-secreting pituitary adenoma or partial resistance to the feedback effect of T4 and T3 on TSH secretion (due to defects in the T3-nuclear receptor) [<a href="#rid15">15,16</a>]. These patients have normal or high serum TSH despite high free T4 and T3 concentrations. (See  <a class="medical medical_review" href="/d/html/7842.html" rel="external">"TSH-secreting pituitary adenomas"</a> and  <a class="medical medical_review" href="/d/html/5827.html" rel="external">"Resistance to thyroid hormone and other defects in thyroid hormone action"</a>.)</p><p class="headingAnchor" id="H1437846"><span class="h2">Critically ill hyperthyroid patients</span><span class="headingEndMark"> — </span>Rarely, patients with hyperthyroidism who are critically ill due to a nonthyroidal illness have normal serum total T4 and normal or even low T3 concentrations. Serum T4 and even free T4 concentrations may be normal because of decreased protein-binding of T4, caused by either low serum concentrations of thyroxine-binding globulin, displacement of T4 from binding proteins by endogenous metabolites or drugs, and other factors. Similar results (low-normal serum T4, normal or low serum T3, and low serum TSH concentrations) are found in euthyroid patients in intensive care units. (See  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>.)</p><p>Since critically ill hyperthyroid patients and many euthyroid critically ill patients have low serum TSH concentrations, identification of those that are hyperthyroid may be difficult [<a href="#rid17">17,18</a>]. The nonthyroidal illness may overshadow or mimic hyperthyroidism (by causing tachycardia, tremor, weakness). Since many critically ill patients have low serum T4 and T3 concentrations, a serum T4 value well within the normal range suggests the possible presence of hyperthyroidism. The diagnosis is further supported by very low serum TSH values, eg, less than 0.01 mU/L. In contrast, detectable but subnormal TSH values (eg, TSH 0.1 to 0.4 mU/L) in an assay with a detection limit of 0.01 mU/L are more consistent with nonthyroidal illness alone [<a href="#rid17">17,18</a>].</p><p>In critically ill patients with suspected hyperthyroidism (TSH &lt;0.01 mU/L and normal serum T4), antithyroid drug therapy should be instituted, with a plan for reassessment after recovery from the nonthyroidal illness.</p><p class="headingAnchor" id="H16194820"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>There are several situations in which the diagnosis of hyperthyroidism may be missed or incorrectly suspected:</p><p class="headingAnchor" id="H16"><span class="h2">Euthyroid hyperthyroxinemia</span><span class="headingEndMark"> — </span>The presence of hyperthyroidism may be incorrectly suspected in patients who have one of several abnormalities in serum thyroid hormone-binding proteins that result in high serum total (and sometimes free) T4 concentrations and normal (or slightly high) T3 concentrations. These patients have normal TSH concentrations and are euthyroid (euthyroid hyperthyroxinemia). (See  <a class="medical medical_review" href="/d/html/7892.html" rel="external">"Euthyroid hyperthyroxinemia and hypothyroxinemia"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Low serum TSH without hyperthyroidism</span><span class="headingEndMark"> — </span>There are other causes of the combination of low serum TSH and normal free T4 and T3 concentrations other than subclinical hyperthyroidism:</p><p class="bulletIndent1"><span class="glyph">●</span>Central hypothyroidism – Some patients with central hypothyroidism have low serum TSH and normal (but usually low-normal) free T4 and T3 concentrations. (See  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/7849.html" rel="external">"Central hypothyroidism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonthyroidal illness – Euthyroid patients with nonthyroidal illness, especially those receiving high-dose glucocorticoids or dopamine, may have low serum TSH but low or low-normal free T4 and very low serum T3 concentrations. (See  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recovery from hyperthyroidism – Serum TSH concentrations may remain low for up to several months after normalization of serum T4 and T3 concentrations in patients treated for hyperthyroidism or recovering from hyperthyroidism caused by thyroiditis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The "physiologic" lowering of serum TSH in pregnancy. (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'hCG and thyroid function'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An altered set point of the hypothalamic-pituitary-thyroid axis in some otherwise healthy older persons [<a href="#rid19">19,20</a>].</p><p></p><p>In hospitalized patients with detectable but subnormal serum TSH concentrations and normal free T4 and T3 concentrations, a practical approach is to reevaluate the patient in four to eight weeks. By that time, it should be apparent whether the low serum TSH value was due to nonthyroidal illness or true thyroid dysfunction. (See  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>.)</p><p class="headingAnchor" id="H1000931044"><span class="h2">Assay interference with biotin ingestion</span><span class="headingEndMark"> — </span>Ingestion of 5 to 30 mg of <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> can cause spurious results in thyroid test assays using biotin-streptavidin affinity systems in their design [<a href="#rid21">21-23</a>]. Biotin will cause falsely low values in immunometric assays (eg, used to measure TSH), and falsely high values in competitive binding assays (eg, used to measure T4, T3, and TSH receptor-binding inhibitor immunoglobulin [TBII or TBI]). These biochemical findings suggest a diagnosis of Graves' disease; however, discontinuation of biotin supplements results in resolution of the biochemical abnormalities. Thyroid tests should be repeated at least two days after discontinuation of biotin supplements.</p><p class="headingAnchor" id="H19"><span class="h1">DETERMINING THE ETIOLOGY</span><span class="headingEndMark"> — </span>Our approach outlined below is consistent with the 2016 American Thyroid Association guidelines for management of hyperthyroidism and other causes of thyrotoxicosis [<a href="#rid24">24</a>]. The approach recommended by the 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism places increased reliance on ultrasonography with color-flow Doppler and measurement of thyroid artery flow velocity and peak systolic velocity for the diagnosis of Graves' disease, and it limits the use of radioiodine imaging to those patients with potential autonomous nodules, or those patients who elect treatment with radioiodine [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H2638295"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Once the diagnosis of hyperthyroidism has been established, the cause of the hyperthyroidism should be determined  (<a class="graphic graphic_algorithm graphicRef133238" data-inline-graphics="133238" href="/d/graphic/133238.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a> and <a class="local">'Thyroid tests'</a> below and <a class="local">'Thyrotropin receptor antibodies'</a> below and <a class="local">'Radioiodine uptake'</a> below.)</p><p>The diagnosis may be obvious on presentation; a patient with new-onset ophthalmopathy, a large non-nodular thyroid, and moderate to severe hyperthyroidism has Graves' disease. However, if the diagnosis is not apparent based on the clinical presentation, diagnostic testing is indicated and can include the following, depending on available expertise and resources:</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of thyrotropin receptor antibodies (TRAb, measured by TSI or TBII [TBI] assays) </p><p class="bulletIndent1"><span class="glyph">●</span>Determination of the radioiodine uptake  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of thyroidal blood flow on ultrasonography</p><p></p><p class="headingAnchor" id="H623202217"><span class="h3">Without nodular thyroid disease</span><span class="headingEndMark"> — </span>For a nonpregnant, hyperthyroid patient without a nodular thyroid and without obvious clinical manifestations of Graves' disease (eg, without ophthalmopathy), measurement of TRAb, determination of radioiodine uptake, or assessment of thyroidal blood flow on ultrasonography are acceptable options to distinguish Graves' disease from other causes of hyperthyroidism  (<a class="graphic graphic_algorithm graphicRef133238" href="/d/graphic/133238.html" rel="external">algorithm 1</a>). We typically measure TRAb first (see <a class="local">'Thyrotropin receptor antibodies'</a> below). If the antibodies are positive, it confirms the diagnosis of Graves' disease. If negative, it does not distinguish among the etiologies, as TRAb may not be elevated in patients with mild Graves' disease [<a href="#rid26">26-28</a>]. In this setting, we proceed with a radioiodine uptake. An alternative is to assess thyroidal blood flow on ultrasound in those centers where expertise is available. (See <a class="local">'Other tests'</a> below.)</p><p class="headingAnchor" id="H3724936386"><span class="h3">With nodular thyroid disease</span><span class="headingEndMark"> — </span>For nonpregnant, hyperthyroid patients with physical examination findings consistent with or suspicious for nodular thyroid disease, we obtain a radioiodine uptake and scan as our initial test to distinguish toxic multinodular goiter (multiple areas of focal increased and suppressed uptake) and toxic adenoma (focal increased uptake) from Graves' disease (diffuse increased uptake) or to assess the functionality of nodules that may coexist with Graves' disease  (<a class="graphic graphic_algorithm graphicRef133238" href="/d/graphic/133238.html" rel="external">algorithm 1</a>). (See <a class="local">'Radioiodine uptake'</a> below.)</p><p>Radioiodine is contraindicated during pregnancy. Thus, for pregnant, hyperthyroid women, we measure TRAb or assess thyroidal blood flow on ultrasonography (where expertise is available). Hyperthyroidism during pregnancy is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes", section on 'Establishing the cause'</a>.)</p><p class="headingAnchor" id="H61539983"><span class="h2">Thyroid tests</span><span class="headingEndMark"> — </span>Sometimes the pattern of thyroid function test abnormalities suggests a specific diagnosis. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>If TSH is low and only serum T3 is high (normal free T4 concentration), the patient most likely has Graves' disease or an autonomously functioning thyroid adenoma. This pattern is more common in regions of marginal iodine intake than in the United States. Another possibility is exogenous T3 (<a class="drug drug_general" data-topicid="9563" href="/d/drug information/9563.html" rel="external">liothyronine</a>) ingestion. T3-hyperthyroidism can also be seen in patients taking antithyroid drugs [<a href="#rid29">29</a>]. A radioiodine scan can differentiate between Graves' disease or autonomy and exogenous intake of T3. (See <a class="local">'Radioiodine uptake'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If TSH is low, free T4 is high, and T3 is normal, the patient may have hyperthyroidism with concurrent nonthyroidal illness, amiodarone-induced thyroid dysfunction, or exogenous T4 ingestion. Patients who ingest exogenous T4 (<a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>) may have high serum T4 and T3 concentrations, but the T3/T4 ratio is lower than that in most patients with Graves' hyperthyroidism and toxic adenoma(s) whose T3/T4 ratio usually exceeds 20 (ng/mcg) [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a> and  <a class="medical medical_review" href="/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If free T4 and T3 are elevated and serum TSH is normal or elevated, serum alpha subunit and a pituitary magnetic resonance imaging (MRI) should be obtained to assess the possibility of a TSH-producing pituitary tumor (see  <a class="medical medical_review" href="/d/html/7842.html" rel="external">"TSH-secreting pituitary adenomas"</a>). Patients with resistance to thyroid hormone have variable degrees of end-organ evidence of hyperthyroidism and a family history of "hyperthyroidism" or genetic abnormalities in the T3 receptor; commercial assays for genetic testing for thyroid hormone resistance are available. (See  <a class="medical medical_review" href="/d/html/5827.html" rel="external">"Resistance to thyroid hormone and other defects in thyroid hormone action"</a>.)</p><p></p><p>The various causes of hyperthyroidism and the tests used to identify them are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/7830.html" rel="external">"Painless thyroiditis"</a> and  <a class="medical medical_review" href="/d/html/7832.html" rel="external">"Subacute thyroiditis"</a> and  <a class="medical medical_review" href="/d/html/7840.html" rel="external">"Exogenous hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules"</a> and  <a class="medical medical_review" href="/d/html/7835.html" rel="external">"Clinical presentation and evaluation of goiter in adults"</a>.)</p><p class="headingAnchor" id="H25975118"><span class="h2">Radioiodine uptake</span><span class="headingEndMark"> — </span>For nonpregnant, hyperthyroid patients with <strong>physical examination suggesting nodular thyroid disease</strong>, we obtain a radioiodine uptake as our initial test to determine the etiology of hyperthyroidism. Pregnancy and breastfeeding are absolute contraindications to radionuclide imaging. However, in the unusual instance where radioiodine uptake measurement is felt to be essential for a definitive diagnosis in a lactating woman, breast milk can be pumped and discarded for five days after ingestion of iodine-123 (123I), then breastfeeding may be resumed [<a href="#rid24">24</a>]; breastfeeding should not be resumed if the iodine-131 (131I) isotope is used for determining the uptake.</p><p>From a pathogenetic viewpoint, hyperthyroidism results from two different mechanisms that can be distinguished by the findings on the 24-hour radioiodine uptake  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism with a <strong>high</strong> (or normal) radioiodine uptake indicates de novo synthesis of hormone  (<a class="graphic graphic_diagnosticimage graphicRef79487" href="/d/graphic/79487.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism with a <strong>low</strong> (nearly absent) radioiodine uptake indicates either inflammation and destruction of thyroid tissue with release of preformed hormone into the circulation or an extrathyroidal source of thyroid hormone, such as in patients with factitious thyrotoxicosis and in patients with struma ovarii, where the functioning thyroid tissue is in the pelvis rather than the neck. Patients who have been exposed to large amounts of iodine (eg, intravenous radiographic contrast, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>) may also have a misleading low radioiodine uptake, although a nearly absent level of uptake after iodine exposure is common only with amiodarone. (See  <a class="medical medical_review" href="/d/html/7824.html" rel="external">"Overview of thyroiditis"</a> and  <a class="medical medical_review" href="/d/html/7840.html" rel="external">"Exogenous hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/7829.html" rel="external">"Struma ovarii"</a> and  <a class="medical medical_review" href="/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a>.)</p><p></p><p>A radioiodine uptake and scan may be indeterminate in a patient with subclinical hyperthyroidism due to an autonomous nodule  (<a class="graphic graphic_diagnosticimage graphicRef51029" href="/d/graphic/51029.html" rel="external">image 2</a>). A suppression scan may better demonstrate an area of focal autonomy  (<a class="graphic graphic_diagnosticimage graphicRef67109" href="/d/graphic/67109.html" rel="external">image 3</a>). Suppression scans are reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules", section on 'Thyroid scintigraphy'</a>.)</p><p class="headingAnchor" id="H143073065"><span class="h2">Thyrotropin receptor antibodies</span><span class="headingEndMark"> — </span>For pregnant, hyperthyroid patients and for nonpregnant, hyperthyroid patients <strong>without nodular goiter</strong> and without obvious clinical manifestations of Graves' disease (eg, without ophthalmopathy), we measure TRAb to determine the etiology of hyperthyroidism. Graves' disease is caused by autoantibodies to the TSH (thyrotropin) receptor that activate the receptor, thereby stimulating thyroid hormone synthesis and secretion as well as thyroid growth (causing a diffuse goiter). The presence of TRAb in serum distinguishes the disorder from other causes of hyperthyroidism.</p><p>In such situations where the clinical diagnosis is uncertain, TRAb, using third-generation assays, have a sensitivity and specificity of 97 and 99 percent for diagnosing Graves' disease when the hyperthyroidism is overt and symptomatic [<a href="#rid27">27</a>]. Therefore, in the presence of TRAb, it is reasonable to assume the diagnosis of Graves' hyperthyroidism [<a href="#rid26">26,31</a>]. However, TRAb may not be positive in patients with mild Graves' disease [<a href="#rid28">28</a>].</p><p>Note that there are two methods for measuring TRAb, and commercial laboratories in the United States may refer to these assays as TBI or TBII (thyrotropin-binding inhibiting or thyrotropin-binding inhibitory immunoglobulin), and thyroid-stimulating immunoglobulin (TSI) assays [<a href="#rid27">27</a>]. Third-generation TBI/TBII assays are competition-based assays that measure inhibition of binding of a labeled, monoclonal, anti-human TRAb (or labeled TSH) to recombinant TSH receptor. In contrast, TSI assays measure immunoglobulin-stimulated increased cAMP production, eg, from Chinese hamster ovary cells transfected with human TSH (hTSH) receptor.</p><p>When TRAb measurement is negative, we then obtain a radioiodine uptake and scan to determine the etiology of the hyperthyroidism. Assessment of thyroid blood flow by ultrasonography is an alternative approach, if expertise is available.</p><p class="headingAnchor" id="H2638251"><span class="h2">Other tests</span><span class="headingEndMark"> — </span>Other measurements that help differentiate Graves' hyperthyroidism from destruction-induced hyperthyroidism when a radioiodine uptake is contraindicated include a serum T3/T4 ratio &gt;20 (in standard units ng/mcg) [<a href="#rid30">30</a>] and a serum free T3/free T4 ratio &gt;0.3 (SI units) [<a href="#rid32">32</a>]. Additionally, assessment of quantitative thyroid blood flow by ultrasonography may be helpful to differentiate Graves' hyperthyroidism from painless thyroiditis [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes", section on 'Establishing the cause'</a> and  <a class="medical medical_review" href="/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Autoimmune thyroid disease'</a>.)</p><p class="headingAnchor" id="H2988658561"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109107.html" rel="external">"Society guideline links: Hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2168.html" rel="external">"Patient education: Antithyroid drugs (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs and symptoms</strong> – Patients with hyperthyroidism may have symptoms that include anxiety, emotional lability, weakness, tremor, palpitations, heat intolerance, increased perspiration, and weight loss despite a normal or increased appetite. The physical examination may be notable for hyperactivity and rapid speech. The presence and size of a goiter depends upon the cause of the hyperthyroidism. Exophthalmos, periorbital and conjunctival edema, limitation of eye movement, and infiltrative dermopathy (pretibial myxedema) occur only in patients with Graves' disease. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid tests in primary hyperthyroidism</strong> – All patients with primary hyperthyroidism have a low thyroid-stimulating hormone (TSH). Many patients with overt hyperthyroidism have high free thyroxine (T4) <strong>and</strong> triiodothyronine (T3) concentrations. In some patients, however, only the serum T3 or serum T4 is elevated  (<a class="graphic graphic_table graphicRef142425" href="/d/graphic/142425.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">In patients with subclinical hyperthyroidism, TSH is below normal (but frequently &gt;0.05 mU/L) and serum free T4, T3, and free T3 are normal. Both overt and subclinical hyperthyroidism are biochemical definitions since hyperthyroid symptoms are nonspecific and may be present in patients with subclinical disease and absent in those with overt disease, especially older adults. (See <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected hyperthyroidism: Testing and diagnosis</strong> – In patients in whom hyperthyroidism is suspected, serum TSH is the best initial test. If subnormal, serum free T4 and T3 concentrations are run by most laboratories that offer a TSH reflex option. If serum free T4 and T3 are not automatically measured when a low serum TSH value is obtained but the index of suspicion for hyperthyroidism is high, a free T4 and T3 should be ordered with the initial TSH measurement. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">In the absence of laboratory error or assay interference, if serum TSH is low and free T4 and T3 are high, the diagnosis of hyperthyroidism is confirmed  (<a class="graphic graphic_table graphicRef142425" href="/d/graphic/142425.html" rel="external">table 1</a>). (See <a class="local">'Overt hyperthyroidism'</a> above and <a class="local">'Assay interference with biotin ingestion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify cause of hyperthyroidism</strong> – Once the diagnosis of hyperthyroidism has been established, the cause of the hyperthyroidism should be determined  (<a class="graphic graphic_algorithm graphicRef133238" href="/d/graphic/133238.html" rel="external">algorithm 1</a>). The diagnosis may be obvious on presentation; a patient with new-onset ophthalmopathy, a large non-nodular thyroid, and moderate to severe hyperthyroidism has Graves' disease. (See <a class="local">'Our approach'</a> above and  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpregnant without nodular thyroid disease</strong> – For a nonpregnant, hyperthyroid patient without a nodular thyroid and without obvious clinical manifestations of Graves' disease (eg, without ophthalmopathy), measurement of TRAb (measured by TSI or TBII [TBI] assays), determination of radioiodine uptake, or assessment of thyroidal blood flow on ultrasonography are acceptable options to distinguish Graves' disease from other causes of hyperthyroidism. We typically measure TRAb first. TRAb should be measured using a third-generation assay. (See <a class="local">'Our approach'</a> above and <a class="local">'Thyrotropin receptor antibodies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpregnant with nodular thyroid disease</strong> – For nonpregnant, hyperthyroid patients with physical examination findings consistent with or suspicious for nodular thyroid disease, we obtain a radioiodine uptake and scan as our initial test to distinguish toxic multinodular goiter (multiple areas of focal increased and suppressed uptake) and toxic adenoma (focal increased uptake) from Graves' disease (diffuse increased uptake) or to assess the functionality of nodules which may coexist with Graves' disease  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 2</a>). (See <a class="local">'Our approach'</a> above and <a class="local">'Radioiodine uptake'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnant or breastfeeding women</strong> – Radioiodine is contraindicated during pregnancy and breastfeeding. Thus, for pregnant, hyperthyroid women, we measure TRAb or assess thyroidal blood flow on ultrasonography (where expertise is available). Hyperthyroidism during pregnancy is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes", section on 'Establishing the cause'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Arch Intern Med 1988; 148:626.</a></li><li><a class="nounderline abstract_t">Trzepacz PT, Klein I, Roberts M, et al. Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989; 87:558.</a></li><li><a class="nounderline abstract_t">Krassas GE, Pontikides N, Kaltsas T, et al. Menstrual disturbances in thyrotoxicosis. Clin Endocrinol (Oxf) 1994; 40:641.</a></li><li><a class="nounderline abstract_t">Kidd GS, Glass AR, Vigersky RA. The hypothalamic-pituitary-testicular axis in thyrotoxicosis. J Clin Endocrinol Metab 1979; 48:798.</a></li><li><a class="nounderline abstract_t">Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996; 44:50.</a></li><li><a class="nounderline abstract_t">Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94.</a></li><li><a class="nounderline abstract_t">Ayres J, Rees J, Clark TJ, Maisey MN. Thyrotoxicosis and dyspnoea. Clin Endocrinol (Oxf) 1982; 16:65.</a></li><li><a class="nounderline abstract_t">Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95:2715.</a></li><li><a class="nounderline abstract_t">Suzuki N, Noh JY, Yoshimura R, et al. Does Age or Sex Relate to Severity or Treatment Prognosis in Graves' Disease? Thyroid 2021; 31:1409.</a></li><li><a class="nounderline abstract_t">Davey RX, Clarke MI, Webster AR. Thyroid function testing based on assay of thyroid-stimulating hormone: assessing an algorithm's reliability. Med J Aust 1996; 164:329.</a></li><li><a class="nounderline abstract_t">Laurberg P, Vestergaard H, Nielsen S, et al. Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 2007; 92:2149.</a></li><li><a class="nounderline abstract_t">Figge J, Leinung M, Goodman AD, et al. The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis. Am J Med 1994; 96:229.</a></li><li><a class="nounderline abstract_t">Caplan RH, Pagliara AS, Wickus G. Thyroxine toxicosis. A common variant of hyperthyroidism. JAMA 1980; 244:1934.</a></li><li><a class="nounderline abstract_t">Bambini G, Aghini-Lombardi F, Rosner W, et al. Serum sex hormone-binding globulin in amiodarone-treated patients. A marker for tissue thyrotoxicosis. Arch Intern Med 1987; 147:1781.</a></li><li><a class="nounderline abstract_t">Wynne AG, Gharib H, Scheithauer BW, et al. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med 1992; 92:15.</a></li><li><a class="nounderline abstract_t">Beck-Peccoz P, Chatterjee VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid 1994; 4:225.</a></li><li><a class="nounderline abstract_t">Spencer C, Eigen A, Shen D, et al. Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. Clin Chem 1987; 33:1391.</a></li><li><a class="nounderline abstract_t">Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. J Clin Endocrinol Metab 1994; 78:1368.</a></li><li><a class="nounderline abstract_t">Lewis GF, Alessi CA, Imperial JG, Refetoff S. Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin Endocrinol Metab 1991; 73:843.</a></li><li><a class="nounderline abstract_t">Mariotti S, Barbesino G, Caturegli P, et al. Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 1993; 77:1130.</a></li><li><a class="nounderline abstract_t">Barbesino G. Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses. Thyroid 2016; 26:860.</a></li><li><a class="nounderline abstract_t">Sharma A, Baumann NA, Shah P. Biotin-Induced Biochemical Graves Disease: A Teachable Moment. JAMA Intern Med 2017; 177:571.</a></li><li><a class="nounderline abstract_t">Li D, Radulescu A, Shrestha RT, et al. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA 2017; 318:1150.</a></li><li><a class="nounderline abstract_t">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.</a></li><li><a class="nounderline abstract_t">Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J 2018; 7:167.</a></li><li><a class="nounderline abstract_t">Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 2010; 10:116.</a></li><li><a class="nounderline abstract_t">Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013; 98:2247.</a></li><li><a class="nounderline abstract_t">Silva de Morais N, Angell TE, Ahmadi S, et al. Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis. Endocr Pract 2022; 28:502.</a></li><li><a class="nounderline abstract_t">Chen JJ, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease. J Clin Endocrinol Metab 1986; 63:102.</a></li><li><a class="nounderline abstract_t">Amino N, Yabu Y, Miki T, et al. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis. J Clin Endocrinol Metab 1981; 53:113.</a></li><li><a class="nounderline abstract_t">Vos XG, Smit N, Endert E, et al. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf) 2008; 69:311.</a></li><li><a class="nounderline abstract_t">Izumi Y, Hidaka Y, Tada H, et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 2002; 57:51.</a></li><li><a class="nounderline abstract_t">Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf) 2007; 67:41.</a></li></ol></div><div id="topicVersionRevision">Topic 7847 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341864" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Graves' disease. Influence of age on clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2816972" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8013145" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Menstrual disturbances in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/372208" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The hypothalamic-pituitary-testicular axis in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8537590" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Differences in the signs and symptoms of hyperthyroidism in older and younger patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1603141" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thyrotoxicosis and the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7074972" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thyrotoxicosis and dyspnoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20392869" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33882721" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Does Age or Sex Relate to Severity or Treatment Prognosis in Graves' Disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606655" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Thyroid function testing based on assay of thyroid-stimulating hormone: assessing an algorithm's reliability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389703" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8154510" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6775100" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Thyroxine toxicosis. A common variant of hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3662707" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Serum sex hormone-binding globulin in amiodarone-treated patients. A marker for tissue thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346235" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7920008" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The variable clinical phenotype in thyroid hormone resistance syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3301067" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200938" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1653784" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077303" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Complex alteration of thyroid function in healthy centenarians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043844" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28192572" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Biotin-Induced Biochemical Graves Disease: A Teachable Moment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973622" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30283735" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807591" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bioassays for TSH-receptor autoantibodies: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539719" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical review: Clinical utility of TSH receptor antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35091101" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2423547" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6165731" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208575" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100069" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437515" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
